Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

Daniel Nomura named editor-in-chief of Molecular Cancer Therapeutics

Daniel K. Nomura was named editor-in-chief of Molecular Cancer Therapeutics, one of the 10 journals published by the American Association for Cancer Research.

February 14, 2025

Vol.51 No.06

Clinical Roundup

Chemo + immunotherapy may improve bladder preservation, interim data from phase II study show

Interim analysis of a clinical trial led by Fox Chase Cancer Center researchers shows promise for the treatment of patients with muscle-invasive bladder cancer.

February 14, 2025

Vol.51 No.06

Clinical Roundup

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.

January 31, 2025

Vol.51 No.04

Clinical Roundup

Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial

Bristol Myers Squibb announced results of an analysis from the three-arm phase III CheckMate-8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo monotherapy across all lines of therapy, including first-line, for the treatment of microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. At a median follow-up of 47 months, Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in the dual-primary endpoint of progression-free survival as assessed by Blinded Independent Central Review versus Opdivo monotherapy (HR 0.62; 95% CI 0.48–0.81; P = 0.0003).

January 31, 2025

Vol.51 No.04

Conversation with The Cancer Letter

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

In 1999, Richard Pazdur, a GI oncologist at MD Anderson, saw an FDA recruitment ad in The New England Journal of Medicine. The agency was looking for a director of the FDA Division of Oncology Drug Products.

Hair growth drug safe at low doses for breast cancer patients, retrospective cohort study shows

A retrospective cohort study in women with breast cancer suggests that low oral doses of minoxidil taken during or after cancer treatment appear to regrow hair in most patients without causing any serious heart-related side effects that require additional therapies or hospitalization.

January 10, 2025

Vol.51 No.01

Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

YOU MAY BE INTERESTED IN

Daniel Nomura named editor-in-chief of Molecular Cancer Therapeutics

Chemo + immunotherapy may improve bladder preservation, interim data from phase II study show

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

Hair growth drug safe at low doses for breast cancer patients, retrospective cohort study shows

Renew today!

Subscriber content

Never miss an issue!

Login